Latest News

Ibrutinib Plus Ofatumumab Tolerable, Active for Relapsed CLL

Ibrutinib Plus Ofatumumab Tolerable, Active for Relapsed CLL

Ibrutinib combined with ofatumumab is well-tolerated and active in patients with relapsed chronic lymphocytic leukemia (CLL).

Prior Myeloproliferative Neoplasm Associated with Poor Outlook in Patients with New Primary Cancers

Prior Myeloproliferative Neoplasm Associated with Poor Outlook in Patients with New Primary Cancers

Preceding myeloproliferative neoplasm is a predictor for poor outlook in patients who develop new primary cancers.

Prognostic Significance of Minimal Residual Disease in Pediatric B-ALL

Prognostic Significance of Minimal Residual Disease in Pediatric B-ALL

Minimal residual disease MRD measured by flow cytometry is highly prognostic in pediatric B-precursor ALL.

Bevacizumab May Add Survival Benefit for Wild-type Proneural Glioblastoma

Bevacizumab May Add Survival Benefit for Wild-type Proneural Glioblastoma

A retrospective analysis showed that first-line bevacizumab treatment may provide overall survival in glioblastoma.

Partner-Assisted Skin Self-Exams Beneficial for Patients with Melanoma

Partner-Assisted Skin Self-Exams Beneficial for Patients with Melanoma

Partner-assisted skin self-examination interventions were efficacious for early detection of individuals with history of melanoma.

In Myelofibrosis, Ruxolitinib Response Associated with Mutation Profile

In Myelofibrosis, Ruxolitinib Response Associated with Mutation Profile

In patients with myelofibrosis treated with ruxolitinib, harboring three or more mutations was inversely associated with response.

Robotic Surgery Viable for Obese Women with Endometrial Cancer

Robotic Surgery Viable for Obese Women with Endometrial Cancer

Robotic surgery is safe and feasible for the surgical management of morbidly obese patients with endometrial cancer.

Link Between Citrus Consumption and Melanoma

Link Between Citrus Consumption and Melanoma

Citrus consumption has been linked to increased risk of malignant melanoma in two cohorts of women and men.

Early Relapse of Follicular Lymphoma Associated with Poor Outcomes

Early Relapse of Follicular Lymphoma Associated with Poor Outcomes

In follicular lymphoma treated with R-CHOP, progression of disease following diagnosis associated with poor outcomes.

Ipilimumab Can Be Infused Safely Over 30 Minutes

Ipilimumab Can Be Infused Safely Over 30 Minutes

Ipilimumab at a dose of 3 mg/kg can be infused safely over 30 minutes with an acceptably low incidence of infusion-related reactions.

Radiotherapy-Induced Malfunction in Cardio Implantable Electronic Devices

Radiotherapy-Induced Malfunction in Cardio Implantable Electronic Devices

Whenever feasible, the use on non-neutron-producing radiotherapy is recommended.

Filgrastim Biosimilar Appears Equally Safe, Effective for Breast Cancer

Filgrastim Biosimilar Appears Equally Safe, Effective for Breast Cancer

Filgrastim are similar with no clinically meaningful differences in efficacy or safety for the prevention of severe neutropenia.

S-1 Plus Sorafenib May Be Safe, Effective for Renal Cell Carcinoma

S-1 Plus Sorafenib May Be Safe, Effective for Renal Cell Carcinoma

Combination therapy with S-1 plus sorafenib is effective and tolerable as treatment for patients with metastatic renal cell carcinoma.

Understanding How Demographics Relate to Breast Cancer Survival

Understanding How Demographics Relate to Breast Cancer Survival

Increased overall mortality in African American women with breast cancer was linked to clinical and socioeconomic factors.

21-Gene Assay Associated with Significant Change in Treatment Decisions

21-Gene Assay Associated with Significant Change in Treatment Decisions

Physicians were more likely to change treatment decisions after evaluating patients using the 21-gene Oncotype DX Assay.

Weekly Oraxol for Second-Line Treatment of Metastatic, Recurrent Gastric Cancer

Weekly Oraxol for Second-Line Treatment of Metastatic, Recurrent Gastric Cancer

Moderate efficacy and favorable toxicity levels of Oraxol as a second-line chemotherapy treatment were observed in gastric cancer.

Treatment-Related Side Effects Associated with Physical Activity in Breast Cancer Survivors

Treatment-Related Side Effects Associated with Physical Activity in Breast Cancer Survivors

Sedentary behavior was associated with increased levels of treatment-related side effects in breast cancer survivors.

Pembrolizumab vs. Chemo for Ipilimumab-Refractory Melanoma

Pembrolizumab vs. Chemo for Ipilimumab-Refractory Melanoma

Pembrolizumab has been shown to improve 6-month progression-free survival for patients with ipilimumab-refractory melanoma.

Bevacizumab with Chemo Improves Survival in Ovarian Cancer with Poor Prognosis

Bevacizumab with Chemo Improves Survival in Ovarian Cancer with Poor Prognosis

When bevacizumab was added to standard chemotherapy, patients with poor prognosis of ovarian cancer had an overall survival benefit.

In Elderly Patients with Breast Cancer, Nab-Paclitaxel Less Safe than EC/CMF

In Elderly Patients with Breast Cancer, Nab-Paclitaxel Less Safe than EC/CMF

Compared with epirubicin and 5-fluorouracil, nab-paclitaxel led to more discontinuations and toxicities in elderly breast cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs